Tarceva, a cancer drug with one of the industry's highest profiles, is quickly propelling OSI Pharmaceuticals
Unfortunately for OSI, that $47.6 million gets cut up. The company has partnered Tarceva with Genentech
Over the next few years, Tarceva is going to mature into a big winner for OSI and Genentech. With AstraZeneca's
The companies also recently reported that Tarceva is effective for the treatment of pancreatic cancer. That is a significant accomplishment; pancreatic cancer is incredibly difficult to treat. Tarceva will probably be approved for this treatment by the end of the year, and uptake should be rapid. Its use in treating two types of cancer virtually assures that the drug will be a major blockbuster.
For now, OSI is essentially the Tarceva story. But that's OK. Building a profitable drug company takes time; the launch of a small company's first drug provides the resources to develop additional products. OSI is beginning to do just that, with another three pre-clinical drugs moving into phase 1 trials by the end of this year.
For additional articles on the biotech industry, see:
- Thanks for the Ride, Transkaryotic
- A Biotech Value Play
- Has Elan Been KO'd?
- Pfizer Pfaces Its Pfuture
- The Best Company I've Never Owned
If you're interested in biotechnology and other exciting industries, check out our Motley Fool Rule Breakers newsletter, whose team is always on the lookout for the best opportunities around. A free trial is yours for the taking.
More from The Motley Fool
GM Proved Doubters Wrong in 2017 With a Strong Crossover Lineup
GM surprised the market when it announced strong guidance thanks to a revamped line of crossovers and SUVs. Better still, it delivered on the promises.
Ford's Behind-the-Scenes Focus on Data
Ford’s recent partnerships and small-scale tests could bode well for the future.
Ford's Tumultuous 2017
Ford’s stock languished behind GM throughout 2017. Will 2018 be a turnaround year?